Healthcare of Ontario Pension Plan Trust Fund Invests $9.14 Million in Tricida, Inc. (NASDAQ:TCDA)


Share on StockTwits

Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Tricida, Inc. (NASDAQ:TCDA) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,295,900 shares of the company’s stock, valued at approximately $9,136,000. Healthcare of Ontario Pension Plan Trust Fund owned about 2.58% of Tricida as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Citigroup Inc. increased its position in Tricida by 180.4% during the 4th quarter. Citigroup Inc. now owns 13,441 shares of the company’s stock worth $95,000 after buying an additional 8,648 shares during the period. ProShare Advisors LLC grew its stake in Tricida by 21.4% during the fourth quarter. ProShare Advisors LLC now owns 14,008 shares of the company’s stock worth $99,000 after buying an additional 2,473 shares in the last quarter. Jane Street Group LLC acquired a new position in Tricida during the fourth quarter valued at approximately $122,000. The Manufacturers Life Insurance Company lifted its position in shares of Tricida by 10.9% during the 4th quarter. The Manufacturers Life Insurance Company now owns 19,407 shares of the company’s stock worth $137,000 after buying an additional 1,914 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of Tricida by 84.2% in the 4th quarter. Wells Fargo & Company MN now owns 23,381 shares of the company’s stock valued at $164,000 after purchasing an additional 10,688 shares in the last quarter. 70.46% of the stock is currently owned by hedge funds and other institutional investors.

Tricida stock opened at $5.11 on Thursday. The stock’s 50 day moving average is $5.43 and its 200 day moving average is $7.11. Tricida, Inc. has a one year low of $3.74 and a one year high of $32.99. The firm has a market cap of $256.75 million, a P/E ratio of -0.95 and a beta of 1.40. The company has a debt-to-equity ratio of 1.11, a current ratio of 7.00 and a quick ratio of 7.00.

Tricida (NASDAQ:TCDA) last released its quarterly earnings results on Thursday, February 25th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.05). Equities analysts anticipate that Tricida, Inc. will post -5.24 earnings per share for the current fiscal year.

Separately, Zacks Investment Research lowered shares of Tricida from a “hold” rating to a “sell” rating in a report on Wednesday, February 10th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $22.00.

In related news, CEO Gerrit Klaerner sold 21,489 shares of the firm’s stock in a transaction that occurred on Monday, January 11th. The stock was sold at an average price of $7.49, for a total transaction of $160,952.61. Following the completion of the sale, the chief executive officer now owns 534,504 shares of the company’s stock, valued at $4,003,434.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sandra I. Coufal sold 5,000 shares of Tricida stock in a transaction that occurred on Tuesday, January 26th. The stock was sold at an average price of $7.06, for a total value of $35,300.00. Following the completion of the sale, the director now owns 167,609 shares of the company’s stock, valued at $1,183,319.54. The disclosure for this sale can be found here. In the last 90 days, insiders sold 53,179 shares of company stock worth $378,092. 70.40% of the stock is owned by company insiders.

Tricida Profile

Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.

See Also: Options Trading

Institutional Ownership by Quarter for Tricida (NASDAQ:TCDA)

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.